Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires $12,000.00 in Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi acquired 10,000 shares of the business’s stock in a transaction on Monday, December 30th. The shares were bought at an average cost of $1.20 per share, with a total value of $12,000.00. Following the completion of the acquisition, the chief executive officer now owns 137,553 shares in the company, valued at approximately $165,063.60. This represents a 7.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Krishna Vaddi also recently made the following trade(s):

• On Wednesday, December 18th, Krishna Vaddi bought 100,000 shares of Prelude Therapeutics stock. The shares were bought at an average price of $0.93 per share, with a total value of $93,000.00.

Prelude Therapeutics Stock Performance

Shares of NASDAQ:PRLD traded down $0.03 on Thursday, reaching $1.25. The company’s stock had a trading volume of 290,187 shares, compared to its average volume of 217,047. The company has a 50-day simple moving average of $1.12 and a 200 day simple moving average of $3.02. Prelude Therapeutics Incorporated has a 52-week low of $0.80 and a 52-week high of $6.80. The company has a market cap of $68.79 million, a P/E ratio of -0.70 and a beta of 1.49.

Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.05. The company had revenue of $3.00 million during the quarter. On average, equities research analysts forecast that Prelude Therapeutics Incorporated will post -1.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PRLD has been the subject of several research reports. JMP Securities reissued a “market outperform” rating and set a $4.00 price objective (down previously from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Prelude Therapeutics in a research report on Friday, November 8th.

Hedge Funds Weigh In On Prelude Therapeutics

Several large investors have recently modified their holdings of PRLD. Barclays PLC lifted its position in Prelude Therapeutics by 86.0% in the third quarter. Barclays PLC now owns 27,165 shares of the company’s stock worth $57,000 after buying an additional 12,564 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Prelude Therapeutics in the third quarter valued at $100,000. Dimensional Fund Advisors LP lifted its holdings in shares of Prelude Therapeutics by 103.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after acquiring an additional 14,769 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Prelude Therapeutics by 32.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after purchasing an additional 15,682 shares during the period. Finally, Walleye Capital LLC grew its holdings in Prelude Therapeutics by 446.2% during the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after purchasing an additional 67,946 shares during the last quarter. Institutional investors own 79.72% of the company’s stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.